INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion

Etwas ausführlicher: Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis https://www.globenewswire.com/news-release/2021/10/21/2318228/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2001-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis.html

Intellia granted Orphan Drug designation for transthyretin amyloidosis program https://newsfilter.io/a/a34daaacd54413360e2cadfaf0fcfc76 • The FDA has granted Orphan Drug designation to Intellia Therapeutics' (NTLA +0.3%) NTLA-2001 treatment for transthyretin amyloidosis ("ATTR"). • The gene editing therapy use a knockout edit to reduce circulating TTR protein levels. • Intellia is partnered with Regeneron Pharmaceuticals (REGN +0.9%) on NTLA-2001. • NTLA-2001 was granted Orphan Drug designation by the European Commission in March.

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress https://www.globenewswire.com/news-release/2021/10/20/2317270/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-Broad-Genome-Editing-Capabilities-at-the-2021-European-Society-of-Gene-Cell-Therapy-Annual-Congres.html • First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatments • Demonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to electroporation • Achieved durable production of normal human alpha-1 antitrypsin protein levels and reduction of endogenous disease-associated protein in non-human primates for the treatment of liver and/or lung manifestations of alpha-1 antitrypsin deficiency (AATD) • Platform advances support acceleration of future drug development candidates from both Intellia’s in vivo and ex vivo research portfolio ...

Kommt dieses Jahr eigentlich noch was an Ergebnissen?🤔

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology https://www.globenewswire.com/news-release/2021/10/13/2313317/0/en/Intellia-Therapeutics-and-SparingVision-Announce-Strategic-Collaboration-to-Develop-Novel-Ocular-Therapies-Using-CRISPR-Cas9-Technology.html • Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise • Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targets • Intellia will receive an equity stake in SparingVision and will have an option to obtain exclusive US commercialization rights for ocular therapies for two targets ...

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema https://finance.yahoo.com/news/intellia-therapeutics-receives-authorization-initiate-113000947.html • NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent attacks in people living with HAE to enter clinical study • NTLA-2002 is Intellia’s second in vivo CRISPR genome editing therapeutic candidate; program to leverage platform insights gained from ongoing development of NTLA-2001 for transthyretin (ATTR) amyloidosis • On track to initiate patient enrollment by year-end ...

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid https://www.globenewswire.com/news-release/2021/09/16/2298323/0/en/Intellia-Therapeutics-Announces-U-S-FDA-Acceptance-of-Investigational-New-Drug-Application-for-NTLA-5001-its-CRISPR-Cas9-Engineered-TCR-T-Cell-Candidate-for-Acute-Myeloid-Leukemia.html • NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical study • NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen on many hematologic malignancies and solid tumors • Initiation of patient screening in Phase 1/2a study of NTLA-5001 expected by year-end ...

🧐🧐🧐

Hey ✌🏼

Es ist so anstrengend zu Sehen wie eine Aktie steigt über mehrere Tage und einfach mal an einem Tag das selbe wieder verliert 🙄🧐

Bobby, auch hier Danke für den Link . Auch hier bin ich investiert 👍

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress Established proof of concept for the Company’s modular in vivo delivery platform with first-ever clinical data from systemically administered CRISPR genome editing candidate in humans Interim Phase 1 data from first two cohorts show NTLA-2001 was well-tolerated and achieved deep TTR reduction, with a maximum 96% serum TTR reduction by day 28, demonstrating potential as single-dose treatment for transthyretin (ATTR) amyloidosis; plan to report additional data from ongoing study this year Plans to initiate first-in-human studies for both NTLA-2002 for hereditary angioedema (HAE) and NTLA-5001 for acute myeloid leukemia (AML) this year Launched CAR T-cell company with Blackstone Life Sciences and Cellex Cell Professionals; concurrent agreement with Cellex gives Intellia access to donor cells and dedicated manufacturing capacity to support wholly-owned ex vivo portfolio Ended the quarter with strong cash position of $551.3 million, and raised an additional $648.1 million of net proceeds from follow-on offering in July

Hey Leute will einsteigen, aber sieht mir nicht danach aus, dass der Kurs nochmal etwas sinkt. Werde wohl den Wert jetzt nehmen müssen. Was meint ihr? Bin mir unsicher.

CRISPR gene-editing treatment could reach patients ‘very, very soon’: Intellia CEO https://www.cnbc.com/2021/07/02/crispr-gene-editing-could-reach-patients-very-soon-intellia-ceo.html KEY POINTS • CRISPR gene editing, which slices DNA to treat diseases, had its first-ever systemic delivery in a human body. • Intellia Therapeutics CEO John Leonard said it was a "major advance in the gene editing space." • Intellia saw its stock rise over 100% in June; 90% in the past week alone since its breakthrough in a collaboration with Regeneron was announced. ...

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock https://www.wallstreet-online.de/nachricht/14113528-intellia-therapeutics-announces-closing-of-690-million-public-offering-of-common-stock

@Nice01 , der ARK Genomic lief im letzten Jahr richtig klasse, in diesem gibt es noch viel Luft nach oben. Ich war aber ausgestiegen, weil er sich hier kaum noch handeln ließ bzw bei der ING nur noch ein Verkauf der Anteile möglich ist. Ähnlich problematisch könnte der Global X Genomics & Biotech ETF sein (WKN A2PH9H). Handelsplatz ist Berlin, aber ein Handel könnte auch in Bezug auf die Verkaufsunterlagen schwierig sein. Dort findest du in den Top 10: Intellia, Genscript, CRISPR, Alnylam, Caredx, Sarepta, Agilent, Arrowhead, PacBio und Biomarin beispielsweise.